Published in J Virol on December 01, 1996
Viral quasispecies evolution. Microbiol Mol Biol Rev (2012) 2.69
Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol (2003) 1.79
Enhancement of hepatitis B virus replication by its X protein in transgenic mice. J Virol (2002) 1.78
Pathogenesis of hepatitis B virus infection. World J Gastroenterol (2007) 1.47
Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation. J Virol (1999) 1.46
Amplification of full-length hepatitis B virus genomes from samples from patients with low levels of viremia: frequency and functional consequences of PCR-introduced mutations. J Clin Microbiol (1998) 1.34
Strong association between genotype F and hepatitis B virus (HBV) e antigen-negative variants among HBV-infected argentinean blood donors. J Clin Microbiol (2004) 1.14
Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. J Viral Hepat (2010) 1.13
Naturally occurring mutations define a novel function of the hepatitis B virus core promoter in core protein expression. J Virol (1998) 1.12
The HNF1/HNF4-dependent We2 element of woodchuck hepatitis virus controls viral replication and can activate the N-myc2 promoter. J Virol (1996) 1.10
Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus. J Virol (2006) 1.05
HLA-DP polymorphisms affect the outcomes of chronic hepatitis B virus infections, possibly through interacting with viral mutations. J Virol (2013) 1.03
Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases. J Virol (2010) 1.00
Core promoter: a critical region where the hepatitis B virus makes decisions. World J Gastroenterol (2014) 0.90
Properties of monoclonal antibodies directed against hepatitis B virus polymerase protein. J Virol (1999) 0.89
Molecular epidemiology of an outbreak of fulminant hepatitis B. J Clin Microbiol (2000) 0.88
The hepatitis B virus core promoter is strongly activated by the liver nuclear receptor fetoprotein transcription factor or by ectopically expressed steroidogenic factor 1. J Virol (2000) 0.86
Novel type of hepatitis B virus mutation: replacement mutation involving a hepatocyte nuclear factor 1 binding site tandem repeat in chronic hepatitis B virus genotype E. J Virol (2005) 0.82
Genotype-dependent activation or repression of HBV enhancer II by transcription factor COUP-TF1. World J Gastroenterol (2006) 0.80
Initial load of hepatitis B virus (HBV), its changing profile, and precore/core promoter mutations correlate with the severity and outcome of acute HBV infection. J Gastroenterol (2007) 0.80
Association between Hepatitis B Virus X Gene Mutations and Clinical Status in Patients with Chronic Hepatitis B Infection. Gut Liver (2011) 0.79
LUC7L3/CROP inhibits replication of hepatitis B virus via suppressing enhancer II/basal core promoter activity. Sci Rep (2016) 0.77
Molecular characterization of hepatitis B virus X gene in chronic hepatitis B patients. Virol J (2012) 0.77
Non-A hepatitis B virus genotypes in antenatal clinics, United Kingdom. Emerg Infect Dis (2007) 0.76
Functional analysis of ground squirrel hepatitis virus enhancer II. J Virol (1998) 0.75
Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature (1979) 15.42
A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res (1991) 13.54
Hepatitis B virus (HBV) particles are produced in a cell culture system by transient expression of transfected HBV DNA. Proc Natl Acad Sci U S A (1987) 4.72
Replication strategy of human hepatitis B virus. J Virol (1987) 4.42
A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol (1995) 3.35
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 3.34
Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med (1991) 2.88
Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol (1994) 2.41
Infectious hepatitis B virus from cloned DNA of known nucleotide sequence. Proc Natl Acad Sci U S A (1985) 2.20
A liver-specific enhancer in the core promoter region of human hepatitis B virus. Science (1989) 1.99
Expression of the hepatitis B virus core gene in vitro and in vivo. J Virol (1987) 1.96
Hepatitis B virus X protein is not central to the viral life cycle in vitro. J Virol (1992) 1.92
Secreted placental alkaline phosphatase as a eukaryotic reporter gene. Methods Enzymol (1992) 1.80
Transcriptional regulation of precore and pregenomic RNAs of hepatitis B virus. J Virol (1992) 1.76
Construction of avian hepadnavirus variants with enhanced replication and cytopathicity in primary hepatocytes. J Virol (1994) 1.66
The precore/core promoter mutant (T1762A1764) of hepatitis B virus: clinical significance and an easy method for detection. J Gen Virol (1995) 1.64
Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med (1995) 1.63
The genome of hepatitis B virus contains a second enhancer: cooperation of two elements within this enhancer is required for its function. J Virol (1990) 1.55
Multiple liver-specific factors bind to the hepatitis B virus core/pregenomic promoter: trans-activation and repression by CCAAT/enhancer binding protein. Proc Natl Acad Sci U S A (1990) 1.54
Hepatocyte-specific expression of the hepatitis B virus core promoter depends on both positive and negative regulation. Mol Cell Biol (1993) 1.50
Translation of the hepatitis B virus P gene by ribosomal scanning as an alternative to internal initiation. J Virol (1993) 1.48
Regulation of hepatitis B virus gene expression by its two enhancers. Proc Natl Acad Sci U S A (1992) 1.45
Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. J Virol (1994) 1.44
Identification of three essential regions of hepatitis B virus X protein for trans-activation function. Oncogene (1992) 1.38
Promoter-specific transactivation of hepatitis B virus transcription by a glutamine- and proline-rich domain of hepatocyte nuclear factor 1. J Virol (1991) 1.28
Sequence rearrangement in JC virus DNAs molecularly cloned from immunosuppressed renal transplant patients. J Virol (1991) 1.26
A new enhancer element, ENII, identified in the X gene of hepatitis B virus. J Virol (1990) 1.23
Identification of a promoter region for 3.6-kilobase mRNA of hepatitis B virus and specific cellular binding protein. J Virol (1989) 1.19
Differential regulation of the hepatitis B virus surface gene promoters by a second viral enhancer. J Biol Chem (1990) 1.18
A liver-specific nuclear factor interacts with the promoter region of the large surface protein gene of human hepatitis B virus. Mol Cell Biol (1989) 1.18
Differentiation-specific transcriptional regulation of the hepatitis B virus nucleocapsid gene in human hepatoma cell lines. Virology (1994) 1.17
C/EBP-like proteins binding to the functional box-alpha and box-beta of the second enhancer of hepatitis B virus. Mol Cell Biol (1991) 1.17
Frequent and rapid emergence of mutated pre-C sequences in HBV from e-antigen positive carriers who seroconvert to anti-HBe during interferon treatment. Virology (1992) 1.15
Overlapping initiator and TATA box functions in the basal core promoter of hepatitis B virus. J Virol (1995) 1.12
Characterization of functional Sp1 transcription factor binding sites in the hepatitis B virus nucleocapsid promoter. J Virol (1993) 1.11
Characterization of a functional hepatocyte nuclear factor 3 binding site in the hepatitis B virus nucleocapsid promoter. Virology (1995) 1.11
Characterization of persistent artifacts resulting from RT-PCR of alternatively spliced mRNAs. Biotechniques (1994) 1.10
Differentiated liver cell specificity of the second enhancer of hepatitis B virus. J Virol (1993) 1.02
Repression of enhancer II activity by a negative regulatory element in the hepatitis B virus genome. J Virol (1994) 0.99
Nucleotide sequence of hepatitis B virus isolated from subjects without serum anti-hepatitis B core antibody. J Med Virol (1995) 0.99
Sequence analysis of hepatitis B virus DNA in immunologically negative infection. Arch Virol (1993) 0.93
Detection of a hepatitis B virus variant with a truncated X gene and enhancer II. Arch Virol (1992) 0.92
Differences in the entire nucleotide sequence between hepatitis B virus genomes from carriers positive for antibody to hepatitis B e antigen with and without active disease. J Med Virol (1994) 0.92
Binding of nuclear factors to functional domains of the duck hepatitis B virus enhancer. J Virol (1993) 0.90
Naturally occurring hepatitis B virus mutants with deletions in the core promoter region. J Hepatol (1994) 0.89
Probable implication of mutations of the X open reading frame in the onset of fulminant hepatitis B. J Med Virol (1995) 0.89
"Silent" hepatitis B virus mutants are responsible for non-A, non-B, non-C, non-D, non-E hepatitis. Microbiol Immunol (1994) 0.87
Modulation of hepatitis B viral antigen expression by immunosuppressive drugs in primary hepatocyte culture. Transplantation (1992) 0.84
Different prevalence of precore mutants in five members of a hepatitis-B-virus-infected family: evidence for a precore variant type in an asymptomatic anti-HBs patient. J Hepatol (1994) 0.79
Precore and contiguous regions of hepatitis B virus in liver transplantation for end-stage hepatitis B. Gastroenterology (1994) 0.79
Alteration in the JC polyomavirus genome is enhanced in immunosuppressed renal transplant patients. Virology (1994) 0.79
Mutations in the transcriptional regulatory region of the precore and core/pregenome of a hepatitis B virus with defective HBeAg production. Fukuoka Igaku Zasshi (1994) 0.77
A new sensitive method for qualitative and quantitative assay of neomycin phosphotransferase in crude cell extracts. Gene (1984) 7.36
Signals regulating hepatitis B surface antigen transcription. Nature (1983) 5.02
Comparative sequence analysis of duck and human hepatitis B virus genomes. J Med Virol (1985) 4.68
Replication strategy of human hepatitis B virus. J Virol (1987) 4.42
Transcripts and the putative RNA pregenome of duck hepatitis B virus: implications for reverse transcription. Cell (1985) 4.41
Levels of physician involvement with patients and their families. A model for teaching and research. J Fam Pract (1994) 3.73
Hepatitis B virus transcription in the infected liver. EMBO J (1984) 3.44
A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol (1995) 3.35
Isolation and characterization of a hepatitis B virus endemic in herons. J Virol (1988) 3.23
Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem (1996) 3.00
Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1. J Cell Biol (1997) 2.98
Cloned HBV DNA causes hepatitis in chimpanzees. Nature (1982) 2.80
Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis. J Immunol (1990) 2.73
Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology (2001) 2.71
The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem (1998) 2.71
Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem (1997) 2.63
Regulation of p53 activity in nuclear bodies by a specific PML isoform. EMBO J (2000) 2.38
IFN enhance expression of Sp100, an autoantigen in primary biliary cirrhosis. J Immunol (1992) 2.24
The nuclear dot protein sp100, characterization of domains necessary for dimerization, subcellular localization, and modification by small ubiquitin-like modifiers. J Biol Chem (1999) 2.21
Infectious hepatitis B virus from cloned DNA of known nucleotide sequence. Proc Natl Acad Sci U S A (1985) 2.20
Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A (1991) 2.05
Putative reverse transcriptase intermediates of human hepatitis B virus in primary liver carcinomas. Science (1986) 2.00
Monoclonal antibodies against chromosomal proteins of Drosophila melanogaster: establishment of antibody producing cell lines and partial characterization of corresponding antigens. Chromosoma (1980) 1.97
Expression of the hepatitis B virus core gene in vitro and in vivo. J Virol (1987) 1.96
The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. J Virol (1992) 1.95
Cloned duck hepatitis B virus DNA is infectious in Pekin ducks. J Virol (1984) 1.80
Expression of hepatitis B antigens with a simian virus 40 vector. J Virol (1984) 1.80
Structure of human ferritin light subunit messenger RNA: comparison with heavy subunit message and functional implications. Proc Natl Acad Sci U S A (1985) 1.79
A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis. Hepatology (2001) 1.78
Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. Virology (1993) 1.75
Generation of stable mRNA fragments and translation of N-truncated proteins induced by antisense oligodeoxynucleotides. Mol Cell (2001) 1.74
[The taxonomic problem of Clostridium sordellii and Clostridium bifermentans]. Med Dosw Mikrobiol (1966) 1.72
Naturally occurring variants of hepatitis B virus. Adv Virus Res (1999) 1.72
Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol (1995) 1.71
Molecular biology of viral and nonviral retroelements. Trends Genet (1989) 1.65
Serological pattern "anti-HBc alone": report on a workshop. J Med Virol (2000) 1.65
Target sequences for cis-acting regulation within the dual promoter of the human c-myc gene. Mol Cell Biol (1987) 1.63
Body language: the function of PML nuclear bodies in apoptosis regulation. Cell Death Differ (2003) 1.62
Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci U S A (1997) 1.60
Indigenous hepatitis E virus infection of a plasma donor in Germany. Vox Sang (2009) 1.60
Detection of an element of the SV40 late promoter in vectors used for expression studies in COS cells. EMBO J (1983) 1.57
Recombination in Tula hantavirus evolution: analysis of genetic lineages from Slovakia. J Virol (1999) 1.54
Partner violence and sexual HIV-risk behaviors among women in an inner-city emergency department. Violence Vict (1998) 1.51
Interferon-modulated expression of genes encoding the nuclear-dot-associated proteins Sp100 and promyelocytic leukemia protein (PML). Eur J Biochem (1996) 1.50
The autoimmune regulator protein has transcriptional transactivating properties and interacts with the common coactivator CREB-binding protein. J Biol Chem (2000) 1.49
Nuclear dots: actors on many stages. Immunobiology (1997) 1.45
Dobrava hantavirus causes hemorrhagic fever with renal syndrome in central Europe and is carried by two different Apodemus mice species. J Med Virol (2001) 1.42
Heterogeneity and common features of defective hepatitis B virus genomes derived from spliced pregenomic RNA. Virology (1997) 1.42
An upper limit on the stochastic gravitational-wave background of cosmological origin. Nature (2009) 1.42
The high-risk sexual practices of crack-smoking sex workers recruited from the streets of three American cities. The Multicenter Crack Cocaine and HIV Infection Study Team. Sex Transm Dis (1998) 1.42
Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allogeneic stem cell transplantation. Gut (2009) 1.40
A new avian hepadnavirus infecting snow geese (Anser caerulescens) produces a significant fraction of virions containing single-stranded DNA. Virology (1999) 1.38
Two nuclear dot-associated proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary cirrhosis. Scand J Immunol (1995) 1.36
Amplification of full-length hepatitis B virus genomes from samples from patients with low levels of viremia: frequency and functional consequences of PCR-introduced mutations. J Clin Microbiol (1998) 1.34
Epitope mapping with a recombinant human 68-kDa (U1) ribonucleoprotein antigen reveals heterogeneous autoantibody profiles in human autoimmune sera. J Immunol (1988) 1.34
Monoclonal antibody directed against RNA polymerase II of Drosophila melanogaster. Mol Gen Genet (1980) 1.33
Internal entry of ribosomes and ribosomal scanning involved in hepatitis B virus P gene expression. J Virol (1989) 1.31
Precore mutant hepatitis B virus infection and liver disease. Gastroenterology (1992) 1.31
Seroprevalence of hantavirus antibodies in Germany as determined by a new recombinant enzyme immunoassay. Eur J Clin Microbiol Infect Dis (1995) 1.28
Hepatitis B virus nucleocapsid/pre-S2 fusion proteins expressed in attenuated Salmonella for oral vaccination. J Immunol (1990) 1.27
PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol (1999) 1.25
Identification and analysis of a new hepadnavirus in white storks. Virology (2001) 1.24
A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. J Hepatol (1990) 1.24
A recombinant Chinese hamster ovary cell line containing a 300-fold amplified tetramer of the hepatitis B genome together with a double selection marker expresses high levels of viral protein. J Mol Biol (1986) 1.23
Enhancement of hepatitis B virus infection by noninfectious subviral particles. J Virol (1998) 1.22
Milk protein-derived peptide inhibitors of angiotensin-I-converting enzyme. Br J Nutr (2000) 1.22
Isolation and characterization of the human hepatic lipase gene. J Biol Chem (1990) 1.22
A new hepatitis B virus variant in a chronic carrier with multiple episodes of viral reactivation and acute hepatitis. Virology (1990) 1.21
Expression mechanism of the hepatitis B virus (HBV) C gene and biosynthesis of HBe antigen. Virology (1989) 1.21
Full-length and truncated versions of the hepatitis B virus (HBV) X protein (pX) transactivate the cmyc protooncogene at the transcriptional level. Biochem Biophys Res Commun (1991) 1.20
Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology (1997) 1.20
Adenovirus type 2 DNA replication. II. Termini of DNA replication. J Virol (1975) 1.18
The interferon (IFN)-stimulated gene Sp100 promoter contains an IFN-gamma activation site and an imperfect IFN-stimulated response element which mediate type I IFN inducibility. J Biol Chem (1996) 1.17
Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J Virol (1997) 1.17
Core particles of hepatitis B virus as carrier for foreign epitopes. Adv Virus Res (1998) 1.17
Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases. Eur J Biochem (1997) 1.16
Hepatitis B virus genomes that cannot synthesize pre-S2 proteins occur frequently and as dominant virus populations in chronic carriers in Italy. Virology (1992) 1.15
Frequent and rapid emergence of mutated pre-C sequences in HBV from e-antigen positive carriers who seroconvert to anti-HBe during interferon treatment. Virology (1992) 1.15
Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. J Hepatol (1999) 1.14
Alterations in thyroid status modulate apolipoprotein, hepatic triglyceride lipase, and low density lipoprotein receptor in rats. Endocrinology (1990) 1.14
Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998. Eur J Epidemiol (2001) 1.14
Growth and nutritional intake of infants with congenital heart disease. Pediatr Cardiol (1989) 1.13
Effect of interferon alpha on hepatitis B virus replication and gene expression in transiently transfected human hepatoma cells. J Hepatol (1999) 1.13
Potent inhibition of hepatitis B virus production in vitro by modified pyrimidine nucleosides. Antimicrob Agents Chemother (1990) 1.12
A recombinant autoantigen derived from the human (U1) small nuclear RNP-specific 68-kd protein. Expression in Escherichia coli and serodiagnostic application. Arthritis Rheum (1988) 1.12
Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G-->A hypermutation. Virology (1997) 1.11
Wild-type levels of pregenomic RNA and replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B virus with C(1653) --> T, A(1762) --> T and G(1764) --> A mutations in the core promoter. J Gen Virol (1998) 1.11
Short report: simultaneous occurrence of Dobrava, Puumala, and Tula Hantaviruses in Slovakia. Am J Trop Med Hyg (1999) 1.11
Upper limits on a stochastic background of gravitational waves. Phys Rev Lett (2005) 1.11
In vitro translation of adenovirus type 12-specific mRNA isolated from infected and transformed cells. J Virol (1979) 1.10
Prevalence and type of pre-C HBV mutants in anti-HBe positive carriers with chronic liver disease in a highly endemic area. Virology (1991) 1.10
Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology (2000) 1.09
Detailed characterization of the binding site of the lipoprotein lipase-specific monoclonal antibody 5D2. J Lipid Res (1998) 1.09